Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study

Neoadjuvant chemotherapy has been proposed as an alternative approach to primary cytoreductive surgery as initial management of bulky ovarian cancer with the aim of improving surgical efficiency and quality of life. The data of a retrospective case-control study including 75 patients with advanced epithelial ovarian carcinoma Stages IIIC and IV are presented. In 20 patients, neoadjuvant chemotherapy (3-5 cycles of cytostatics) was applied before cytoreductive surgery which was followed by chemotherapy, six cycles in total. In 55 patients cytoreductive surgery was applied as the primary treatment followed by six cycles of chemotherapy. A comparison of both groups of patients showed no significant difference regarding patient age, tumor stage, grade and treatment modality (chemotherapy and surgery, without irradiation) applied cytostatics and total number of chemotherapeutic cycles. The data from our study confirmed a statistically significant difference in radicality of cytoreduction that was more extensive when applied in combination with neoadjuvant chemotherapy than when applied as primary cytoreductive surgery (p = 0.009). No statistically significant difference was found in the survival of the two groups (p = 0.79), the response to primary treatment (p = 0.52), relapse (p = 0.88) or disease-free survival (p = 0.61). From the findings of the study and literature review, we may conclude that neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced epithelial ovarian carcinoma does not have an unfavorable effect on the prognosis.

Neoadjuvant chemotherapy; Primary cytoreductive surgery; Advanced ovarian cancer

[1] Cancer Registry of Slovenia. Cancer incidence in Slovenia, 1998, Report No 38.

[2] Aure J. C., Hoeg K., Kolstad P.: "Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases". Obstet. Gynecol., 1971, 58, 131.

[3] Hoskins W. J., Lawton F. G.: "Primary cytoreductive surgery for advanced stage disease". In Gershenson D. M., McGuire W. P.(eds.), Ovarian Cancer. New York: Churchill Livingstone, 1998, 65.

[4] Vergote I. B., De Wever I., Tjalma W. et al.: "An alternative for primary surgical debulking?". Semin. Surg. Oncol., 2000, 19, 49.

[5] Heintz A. P., Hacker N. F., Berek I. S. et al.: "Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity". Obstet. Gynecol., 1986, 67, 783.

[6] Hoskins W. Y., McGuire W. P., Brady M. F. et al.: "The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.

[7] Vergote I. B., De Wever I., Tjalma W. et al.: "Neoadjuvant chemotherapy in advanced ovarian cancer: time for a prospective randomized study". Int. J. Gynecol. Cancer, 1999, 9 (Suppl), 52.

[8] Lawton F. G., Redman C. W. E., Luesly D. M. et al.: "Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer". Obstet. Gynecol., 1989, 73, 61.

[9] Jacob J. H., Gerhenson D. M., Morris M. et al.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oneal., 1991, 42, 46.

[10] Lim J. T. W., Green J. A.: "Neoadjuvant carboplatin and ifosfamid chemotherapy for inoperable FIGO Stage III and IV ovarian carcinoma". Clin. Oneal., 1993, 5, 198.

[11] Shimizu Y., Hasumi K.: "Treatment of stage III and IV ovarian cancer - is neoadjuvant chemotheraoy effective?". Nippon Sanka Fujinka Gakkai Zasshi, 1993, 45, 1007.

[12] Onnis A., Marchetti M., P adovan P. et al.:" Neoadjuvant chemotherapy in advanced ovarian cancer". Eur. J. Gynec. Oneal., 1996, 17 (5), 393.

[13] Surwit E.,C hilders J.,A tlas I. et al.: "Neoadjuvant chemotharapy for advanced ovarian cancer". Int. J. Gynecol. Cancer, 1996, 6, 356.

[14] Schwartz P. E., Rutheford T. J., Chambers L. J. et al.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival". Gynecol. Oncol., 1999, 72, 93.

[15) Kuhn W., Rutke S., Spathe K. et al.: "Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma". Cancer, 2001, 92 (10), 2585.

[16] Kayikipg Lu F., Kse M. F., Boran N. et al.: "Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian cancer". Int. J. Gynecol. Cancer, 2001, 11 (6), 466.

[17] Ansquer Y., Leblanc E., Clough K. et al.: "Neoadjuvant chemotherapy for unresectable ovarian carcinoma". Cancer, 2001, 91(12), 2329.

[18] Vergote I. B., De Wever I., Tjalma W. et al.: "Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian cancer: a retrospective analysis of 258 patients". Gynecol. Oncol., 1998, 71, 431.

[19] Eisenkop S. M., Friedman R. L., Wang H. J.: "Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study". Gynecol. Oncol., 1998, 69, 103

[20] Allen D. G., Heintz A. P., Touw F. W.: "A meta-analysis of residual disease and survival in stage III and IV of the ovary". Eur. J. Gynecol. Oncol., 1995, 16, 349.

[21] Kuhn W.，FkloracK G.，Roder J. et al.： “ The mfluence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV". Int. J. Gynecol. Cancer, 1998, 8, 56.

[22] Hudson C. N.: "Surgical treatment of ovarian cancer". Gynecol. Oneal., 1973, 1, 370.

[23] Eisenkop S. M., Spirtos N. M., Friedman R. L.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Gynecol. Oneal., 1999, 74, 311.

[24] Van Der Burg M. E. L., Van Lent M., Buyse M. et al.: "The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study". N. Engl. J. Med., 1995, 332, 629.

[25] FIGO: "Annual Report on the Results of Treatment in Gynecological Cancer". J. of Epidemiol. Biostat., 2001, 6, 1.